Assessing B-cell depletion and disease activity in a french multiple sclerosis cohort treated by long-term anti-CD20 antibody therapy

被引：0
|
作者：
Freeman, S. [1 ]
Lemarchant, B. [1 ,2 ]
Alberto, T. [1 ]
Drelon, A. [1 ]
Boucher, J. [1 ]
Dubucquoi, S. [3 ]
Zephir, H. [1 ,2 ]
机构：
[1] Univ Lille, Dept Neurol, CRC SEP, CHU Lille, Lille, France
[2] Univ Lille, INSERM, CHU Lille, Lille, France
[3] Univ Lille, INSERM, CHU Lille, U1286,INFINITE Institute Translat Res Inflammat, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P328
引用
收藏
页码：355 / 356
页数：2
相关论文
共 50 条
  • [1] Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy
    Freeman, Sean A.
    Lemarchant, Bruno
    Alberto, Tifanie
    Boucher, Julie
    Outteryck, Olivier
    Labalette, Myriam
    Rogeau, Stephanie
    Dubucquoi, Sylvain
    Zephir, Helene
    NEUROTHERAPEUTICS, 2023, 20 (06) : 1707 - 1722
  • [2] Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy
    Sean A. Freeman
    Bruno Lemarchant
    Tifanie Alberto
    Julie Boucher
    Olivier Outteryck
    Myriam Labalette
    Stéphanie Rogeau
    Sylvain Dubucquoi
    Hélène Zéphir
    Neurotherapeutics, 2023, 20 : 1707 - 1722
  • [3] Anti-CD20 Antibody Therapy for B-Cell Lymphomas
    Calcagno, Andrea
    Rostagno, Roberto
    Di Perri, Giovanni
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09): : 877 - 878
  • [4] Anti-CD20 Antibody Therapy for B-Cell Lymphomas
    Maloney, David G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (21): : 2008 - 2016
  • [5] Evaluation of the optimal anti-CD20 treatment strategy for long-term B-cell depletion in mice
    Hecker, C.
    Dietrich, M.
    Hartung, H. -P.
    Albrecht, P.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 653 - 654
  • [6] Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis
    Fox, E.
    Steinman, L.
    Hartung, H.
    Alvarez, E.
    Qian, P.
    Wray, S.
    Robertson, D.
    Huang, D.
    Selmaj, K.
    Wynn, D.
    Weiss, M. S.
    Bosco, J. A.
    Power, S. A.
    Mok, K. A.
    Lee, L.
    Cree, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 68 - 68
  • [7] B-cell depletion in patients with multiple myeloma with the anti-CD20 monoclonal antibody rituximab after high dose therapy
    Witzens, M
    Gemmel, C
    Moos, M
    Goldschmidt, H
    Ho, AD
    BONE MARROW TRANSPLANTATION, 1999, 23 : S141 - S141
  • [8] B-cell depletion by anti-CD20 antibody treatment in rheumatoid arthritis modulates the B-cell repertoire.
    Rouzière, AS
    Kneitz, C
    Dörner, T
    Tony, HP
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S138 - S138
  • [9] Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
    Roach, Charles A.
    Cross, Anne H.
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [10] Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice
    Zhang, Ai-Hong
    Skupsky, Jonathan
    Scott, David W.
    BLOOD, 2011, 117 (07) : 2223 - 2226
12345